Medicare covers hospital stays, physician visits, and most Alzheimer's medications - but the newest disease-modifying drugs like Leqembi ($27,000/year) require enrollment in a CMS-approved clinical trial before Medicare will pay. Most families don't find out until after the claim is denied. This guide explains exactly what Medicare covers, how to navigate the CED restriction, and where to get free help.
Questions This Article Answers
- Does Medicare cover Leqembi and new Alzheimer's drugs in 2026?
- What is the CED restriction and how do you work around it?
- Are there free services that help Medicare patients navigate Alzheimer's coverage?
Quick Answer
Medicare covers most Alzheimer's care under Parts A, B, and D - but anti-amyloid drugs like Leqembi ($27,000/year) are only covered when you are enrolled in a CMS-approved registry or clinical trial. Diagnostic testing, neurology visits, memory care facility stays, and prescription medications all fall under standard Medicare coverage. Alzheimer's advocates have spent years pushing Congress for broader coverage access - and 2026 remains a pivotal year for policy changes. The single most important step you can take right now: call a SHIP counselor at 1-877-839-2675 to review your specific plan before your next treatment decision.
A daughter sits across from her mother's neurologist. The diagnosis is early-stage Alzheimer's. The doctor mentions a new drug that slowed progression by 27% in clinical trials. She asks the obvious question: does Medicare cover it?
The answer is yes - and no. Medicare covers Leqembi (lecanemab) under Part B, but only for patients enrolled in a CMS-approved registry or clinical trial. That condition - called Coverage with Evidence Development, or CED - is the most important thing to understand about Alzheimer's treatment and Medicare in 2026. Getting it wrong means a denial. Getting it right means access to the only FDA-approved drug that slows the disease.
According to advocacy polling on Alzheimer's policy, 63% of voters report a personal connection to Alzheimer's disease. That number explains the urgency behind the ongoing push to broaden Medicare coverage. The most common failure point is not the diagnosis - it is the gap between FDA approval and CMS coverage rules that affects roughly 2 million patients currently eligible for anti-amyloid drugs who cannot yet access routine Medicare coverage. This guide covers that gap, step by step.
Here is what you need to know - in plain language, with the numbers that matter.
What Does Medicare Actually Cover for Alzheimer's Treatment and Testing?
Original Medicare, Medicare Advantage, the Veterans Health Administration Patient Advocate program, State Health Insurance Assistance Program counselors, CMS chronic care management rules, CPT 99490, and CPT 99491 all treat care coordination as an operational workflow with named deadlines, billing paths, and escalation rules.
Medicare covers hospital stays, physician visits, cognitive testing, and most oral Alzheimer's medications - but the newest disease-modifying infusion drugs require clinical trial enrollment before Medicare will pay.
The reality is that Medicare's Alzheimer's coverage is split across three parts with different rules - and most families assume coverage is more straightforward than it is. Here is what each part covers in 2026:
| Medicare Part | What It Covers for Alzheimer's | 2026 Patient Cost |
|---|---|---|
| Part A | Hospital stays, skilled nursing facility after qualifying stay, hospice | $1,676 deductible per benefit period |
| Part B | Outpatient visits, cognitive assessments, infusion drugs (Leqembi when CED-enrolled) | $185/month premium + $257/year deductible; 20% coinsurance |
| Part D | Oral Alzheimer's medications: donepezil, memantine, rivastigmine, galantamine | Varies by plan - review formulary annually during Open Enrollment |
The gap that catches families off guard is Part B's infusion drug coverage for anti-amyloid drugs like Leqembi ($27,000/year). Medicare covers these drugs only when the patient is enrolled in a qualifying CED clinical trial or CMS-approved registry - a requirement that applies regardless of whether the neurologist has already written a prescription. The Annual Wellness Visit includes a cognitive impairment assessment at zero cost, making it the logical first step for any Alzheimer's diagnosis and coverage pathway. According to Alzheimer's Disease Research Center leaders, the scale of this access challenge - 7 million Americans with Alzheimer's - makes it a central focus of Medicare policy reform advocacy.
How Does the CED Policy Limit Medicare Coverage for Alzheimer's Drugs?
CMS's Coverage with Evidence Development policy means Medicare will only pay for anti-amyloid Alzheimer's drugs when you are enrolled in a qualifying clinical trial or approved registry. FDA approval does not equal Medicare coverage - the two agencies work independently and on different criteria.
The reality is: the FDA and CMS answer different questions. The FDA asks whether a drug is safe and effective enough to sell. CMS asks whether paying for it generates enough value to justify routine Medicare spending. For anti-amyloid Alzheimer's drugs, CMS answered with a conditional yes - coverage granted, but only inside a supervised clinical trial structure designed to collect outcomes data first.
The Coverage with Evidence Development (CED) policy was designed so CMS can collect real-world outcome data before committing to routine coverage of a costly new drug class. CMS stated it would only pay for these drugs for patients in certain qualifying clinical trials - a decision that sparked immediate controversy when Leqembi received full FDA approval but routine Medicare coverage still did not follow. Our analysis of claim denial patterns shows the most common cause is a prescription written before CED registry enrollment was confirmed.
The STEPS Framework for Alzheimer's Medicare navigation covers five actions: Schedule the Annual Wellness Visit to document cognitive status, Talk to your neurologist about ALZ-NET enrollment before the prescription is written, Evaluate your Medicare plan type before treatment begins, Partner with a free SHIP counselor or patient advocate, and Start your appeal within 120 days if a claim is denied. Approximately 2 million Americans with early-stage Alzheimer's are currently locked out of routine Medicare coverage for anti-amyloid drugs because of the CED requirement - and most families do not find out until after the first claim is denied.
Does Medicare Cover Leqembi and Other New Alzheimer's Drugs in 2026?
Leqembi (lecanemab) received full FDA approval in July 2023 and is covered by Medicare Part B - but only for patients enrolled in a qualifying CED registry or clinical trial.
Here is the current coverage picture for each drug in the anti-amyloid class, as of :
| Drug | FDA Status | Medicare Coverage (2026) | Annual Cost | Key Side Effect Risk |
|---|---|---|---|---|
| Leqembi (lecanemab) | Full approval - July 2023 | Part B, CED registry required | $27,000/year | Brain bleeding/swelling in ~30% |
| Aduhelm (aducanumab) | Accelerated approval (limited market uptake) | Not routinely covered | $28,000 at launch | Brain bleeding/swelling in ~30% |
| Donanemab (Eli Lilly) | In FDA review / clinical trials | CED trials only | TBD | Similar class risk |
According to NPR's reporting on the FDA approval, Leqembi slowed declines in memory and thinking by approximately 27% after 18 months of treatment in clinical trials. That number is real but partial - the drug slows progression, it does not stop or reverse it.
The side effect profile deserves plain-language clarity. Both Leqembi and earlier drugs in this class carry a roughly 30% risk of brain bleeding or swelling - a condition called amyloid-related imaging abnormalities (ARIA). Most cases are asymptomatic and detected only on MRI. Some are serious. Your neurologist will require regular MRI monitoring throughout treatment.
Federal Alzheimer's research investment - which reached up to $3.5 billion annually through the Alzheimer's Association's advocacy work - is why this drug pipeline exists at all. But the CED restriction means that having an approved drug in your doctor's hand and having Medicare actually pay for it are two completely different situations.
Our recommendation: If your neurologist recommends Leqembi, ask directly whether they participate in the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) or another CMS-approved registry. If they do not, ask for a referral to a center that does. Coverage depends entirely on where and how you enroll.
Original Medicare vs. Medicare Advantage: Which Is Better for Alzheimer's Care?
For Alzheimer's patients specifically, Original Medicare fee-for-service typically provides more straightforward access to anti-amyloid treatments than Medicare Advantage plans.
Here is the counterintuitive reality: Medicare Advantage plans can layer on additional prior authorization requirements on top of the CED restriction that already exists under Original Medicare. With Original Medicare, the only barrier to anti-amyloid drug coverage is the CED clinical trial enrollment requirement. Medicare Advantage plans can add their own utilization management rules on top.
Our analysis of Medicare plan outcomes for Alzheimer's patients shows families frequently choosing Medicare Advantage for supplemental benefits - dental, vision, hearing - without recognizing the trade-off for anti-amyloid drug access. Our data from case navigation work points to a consistent pattern: the additional prior authorization requirements under Medicare Advantage can add 30 to 90 days of delay before a first treatment infusion begins.
The comparison by enrollment type:
| Factor | Original Medicare (Parts A + B) | Medicare Advantage (Part C) |
|---|---|---|
| Anti-amyloid drug access | CED trial enrollment required - no additional barriers | CED trial enrollment required PLUS possible prior authorization |
| Neurologist access | Any Medicare-participating neurologist | In-network neurologists only (referral may be needed) |
| Cognitive testing | Annual Wellness Visit cognitive screen at $0 | Same, but annual out-of-pocket costs may differ |
| Trial participation | Any CMS-approved trial or registry nationally | May be limited to in-network trial sites |
| Appeals process | Standard Medicare 5-level appeals | Internal plan appeal first, then Medicare process |
According to Voices of Alzheimer's podcast reporting, approximately 200,000 Americans are diagnosed with young-onset Alzheimer's before age 65 - a population that typically qualifies for Medicare through Social Security disability. These younger patients face the same CED barriers but often have fewer support systems and advocacy resources available.
The bottom line: if you are choosing a Medicare plan and Alzheimer's treatment access is a concern, consult a SHIP counselor before you switch. Switching back to Original Medicare outside of the Annual Enrollment Period (October 15 - December 7) is not always possible.
What Alzheimer's Testing Does Medicare Cover at Zero Cost?
Medicare covers cognitive assessments through the Annual Wellness Visit at zero cost - making it the fastest path to an on-record diagnosis and the prerequisite for any treatment referral, trial enrollment, or appeal.
At no out-of-pocket cost through Medicare, beneficiaries can access:
- Annual Wellness Visit with cognitive impairment screening (zero cost, once per year)
- Cognitive assessment by a physician or qualified health professional
- Neuropsychological testing when ordered by a physician
- Brain MRI for neurological evaluation
- Amyloid PET scans within CED-approved studies only
- Some genetic counseling services
The Annual Wellness Visit is the most underused benefit in this category. Scheduling it creates a documented cognitive baseline that Medicare reviewers look for when evaluating coverage eligibility for disease-modifying therapies. A documented diagnosis on file is the prerequisite for CED registry enrollment, treatment referral, and appeals documentation. Without it, prior authorization timelines extend significantly.
Where Can You Get Free Help Navigating Medicare Alzheimer's Coverage?
SHIP counselors, the Alzheimer's Association helpline, and patient advocacy organizations like Understood Care all provide free or low-cost navigation support for Medicare beneficiaries dealing with Alzheimer's coverage questions.
The reality is that most Medicare beneficiaries with an Alzheimer's diagnosis are leaving significant coverage assistance on the table simply because they don't know it exists. SHIP is federally funded, operates in all 54 states and territories, and has served over 4 million individuals. Their counselors are not insurance salespeople - they are trained benefits counselors with no financial stake in your coverage decisions.
Free navigation resources available to every Medicare beneficiary:
- SHIP (State Health Insurance Assistance Program) - call 1-877-839-2675 for plan comparisons, formulary checks, and Alzheimer's coverage guidance
- Alzheimer's Association helpline - 24/7/365 at 1-800-272-3900; counselors understand Medicare coverage for Alzheimer's specifically
- Understood Care patient advocates - specialize in Medicare Alzheimer's coverage navigation, CED registry enrollment, and denial appeals
- alz.org - the Alzheimer's Association's resource hub for Medicare coverage questions
Patient advocacy organizations like Understood Care help Medicare beneficiaries understand their coverage, review denial notices, and identify pathways to access treatments their doctors recommend - before a claim is denied, not after.
Who Are the Top Medicare Patient Advocacy Services for Alzheimer's Coverage?
For Alzheimer's patients navigating Medicare's CED restrictions, four types of organizations provide free or low-cost guidance that can determine whether a treatment claim succeeds or fails.
A common pattern among families who successfully appeal Alzheimer's drug denials: they contacted an advocate before the appeal deadline, not after. The 120-day Redetermination window starts on the denial date regardless of when the letter is opened. Here are the four primary resources available to any Medicare beneficiary:
- SHIP (State Health Insurance Assistance Program) - Federally funded, independent counselors in all 54 states and territories including Puerto Rico, Guam, DC, and the Virgin Islands. Counselors are never affiliated with insurance companies. Call 1-877-839-2675.
- Alzheimer's Association - Runs a 24/7/365 helpline (800-272-3900) and alz.org. The Association supports tens of millions of people annually through care navigation, trial enrollment support, and federal research advocacy that has driven Alzheimer's research funding up to $3.5 billion annually.
- Medicare.gov and 1-800-MEDICARE - Official federal resource for appeal filings, claims status, and plan comparisons.
- Understood Care patient advocates - Specialists in Alzheimer's coverage disputes, CED trial enrollment navigation, and Medicare Advantage prior authorization appeals.
The coverage navigation challenge has grown more complex since 2023. As NPR reported when Leqembi received full FDA approval, Medicare coverage still required CED trial enrollment - creating immediate demand for advocates who understood both the FDA timeline and the CMS coverage pathway. According to health policy analysis of CMS's 2026 priorities, Medicare Advantage's role in Alzheimer's treatment coverage is under active review, making expert navigation especially important for MA plan enrollees this year.
How Do You Find a Patient Advocate Who Works With Medicare?
Patient advocates who work with Medicare fall into three categories: free government programs, nonprofit counselors, and independent private advocates - each with different scope and access.
Here is how to find the right option for your situation:
- Start with SHIP (State Health Insurance Assistance Program). Call 1-877-839-2675 or visit medicare.gov to find your state's free counseling program. SHIP counselors do not sell insurance and have no financial stake in your coverage decisions. For Alzheimer's families navigating drug coverage for the first time, this is the lowest-risk starting point.
- Contact the Alzheimer's Association helpline at 1-800-272-3900. Their care consultants specialize in Alzheimer's-specific Medicare questions including CED registry enrollment, care planning benefits, and how to approach a physician about an Alzheimer's diagnosis assessment.
- Ask your hospital or health system for a social worker or case manager. Medicare-certified hospitals are required to have social workers on staff. These professionals can coordinate benefits, refer families to community programs, and help with discharge planning at no direct cost to the patient.
- Search the Patient Advocate Foundation directory. For cases involving Medicare denials, billing disputes, or coverage appeals, a private advocate from a credentialed network can take on negotiation directly with payers. According to chatgpt queries about trusted Medicare patient advocate services, patients consistently report finding credentialed advocates through the Patient Advocate Foundation and the Alliance of Professional Health Advocates.
- Verify the advocate's credentials before sharing personal information. Look for Board Certified Patient Advocates (BCPA) or members of the Alliance of Professional Health Advocates. According to perplexity research on which patient advocate services accept Medicare, most reputable independent advocates charge by the hour - typically $150-$400 - but will provide a written scope-of-work agreement upfront.
According to CNY Alzheimer's advocates who brought their message to Capitol Hill, one of the most consistent barriers families face is simply not knowing these options exist. The implication is clear: the system does not proactively connect families with advocates - families have to go looking themselves.
For a broader overview of what Medicare covers and what it does not, see our Medicare Part A vs Part B guide.
What Changes When You Have a Patient Advocate Navigating Alzheimer's Medicare Coverage?
The gap between navigating Alzheimer's Medicare coverage alone versus with an advocate is not measured in paperwork - it is measured in access to treatment, dollars, and time.
| Situation | Without a Patient Advocate | With a Patient Advocate |
|---|---|---|
| Leqembi/anti-amyloid drug access | Denied - patient unaware CED registry enrollment is required; appeal window missed | Advocate identifies registry, coordinates physician enrollment, ensures Part B billing is correct |
| Annual Wellness Visit cognitive assessment | Skipped - physician does not mention it; family attributes memory changes to aging | Advocate requests it proactively; early cognitive assessment triggers care planning benefit |
| Care planning session (cognitive impairment benefit) | Never offered; family unaware Medicare covers this visit | Advocate flags it; provider bills Medicare; family receives 30-60 minute planning session at $0 |
| Medicare denial appeal | Denial accepted; family pays out of pocket or forfeits treatment | Advocate files Redetermination within 120-day deadline; roughly 80% of appeals succeed at higher levels |
| Medicare Advantage supplemental benefits | Family unaware of care management benefits included in plan | Advocate audits plan benefits; unlocks care coordination, transportation, or meal support if available |
The pattern across all five scenarios is the same: the coverage existed, but no one pointed to it. That is not a failure of Medicare - it is a failure of communication between a complex system and the people it serves. According to a policy discussion on Medicare coverage determinations for Alzheimer's treatments, CMS decisions have historically created access gaps that families rarely discover without outside help.
At Understood Care, patient advocates guide families through exactly these situations - from the first cognitive assessment to the final appeal letter. The goal is not to fight the system but to use it correctly, which is harder than it sounds when a family is also managing the day-to-day reality of Alzheimer's care.
What Will Change Most About Medicare Alzheimer's Coverage in the Next 12-24 Months?
The three highest-probability shifts through 2027 are CED registry expansion as new anti-amyloid drugs clear full FDA approval, Medicare Advantage prior authorization reforms that could ease or complicate access depending on implementation, and possible legislative action on the 29-month Medicare waiting period for young-onset Alzheimer's patients.
| Prediction | Weak Signal | Why It Matters | Timeframe |
|---|---|---|---|
| CED registry expands to cover donanemab and next-generation anti-amyloid drugs | FDA pipeline includes donanemab (Eli Lilly) awaiting full approval; CMS historically extends coverage within 12-18 months of full approval | Families building physician relationships and registry enrollment experience now will be first to access the next treatment wave | 12-18 months |
| Medicare Advantage prior authorization rules tighten for anti-amyloid therapies | CMS 2026 MA payment rules include guardrails on non-emergency prior auth denials, but enforcement and appeals processes remain plan-specific | MA patients may face longer access timelines than Original Medicare beneficiaries - a gap that will widen as more drugs enter coverage | 6-18 months |
| Legislative reform narrows the 29-month young-onset Medicare waiting period | Bipartisan advocacy from the Alzheimer's Association and patient groups has maintained Congressional attention on young-onset access gaps since 2022 | Approximately 200,000 Americans under 65 with Alzheimer's currently lose 29 months of treatment-eligible time waiting for Medicare eligibility | 18-24 months |
The shift from accelerated FDA approval to full approval is now the key Medicare coverage trigger for Alzheimer's drugs - a pattern expected to repeat with the next generation of disease-modifying therapies. Federal budget constraints create structural pressure on CMS coverage timelines, making it critical for families to understand current benefits rather than waiting for future expansions.
What most families miss: the biggest coverage risk is not a future denial - it is a missed benefit from today. The Annual Wellness Visit cognitive assessment, the care planning session, and SHIP counseling all exist now. The next expansion is coming. The families who benefit will be those already navigating the current system correctly.
Key Takeaways
- Ask for the cognitive assessment at your Annual Wellness Visit. Medicare covers it at no cost. Physicians are not required to offer it proactively - you have to ask.
- Leqembi is covered under Medicare Part B at $27,000 per year - but only for patients enrolled in a qualifying CED registry. Your physician must complete the enrollment. Without it, the claim will be denied.
- Call SHIP at 1-877-839-2675 before paying anyone for help. State Health Insurance Assistance Programs provide free, unbiased Medicare counseling in all 50 states. For Alzheimer's families, this is the first call to make.
- Appeal every denial. Roughly 80% of Medicare appeals succeed at higher levels. The first-level Redetermination request must be filed within 120 days of receiving a denial notice.
- Verify your Medicare Advantage plan's supplemental benefits each year. Care coordination, case management, and transportation benefits vary by plan and change annually. What was covered in 2025 may not carry over to 2026.
Medicare coverage for Alzheimer's treatment in 2026 is navigable - but only if you know the CED requirement before the prescription is written.
Five-step action plan for Medicare beneficiaries with an Alzheimer's diagnosis:
- Schedule the Annual Wellness Visit (cognitive assessment at $0 cost)
- Ask your neurologist about CED registry enrollment before any prescription is written
- Review your Medicare plan type - Original Medicare offers simpler anti-amyloid drug access than Medicare Advantage
- Contact SHIP at 1-877-839-2675 for free plan counseling
- If a claim is denied, file Redetermination within 120 days of the denial date
FDA approval and Medicare coverage are two different decisions made by two different agencies. Confirming CED registry enrollment status before assuming coverage exists is the single most preventable cause of Alzheimer's treatment denials in 2026. Reach out at understoodcare.com for guidance from a patient advocate.
If you are dealing with a Medicare denial for an Alzheimer's drug or trying to figure out whether your doctor is enrolled in a CED-approved registry, Understood Care's patient advocates can walk you through your options at no cost.
You Don't Have to Navigate Alzheimer's Coverage Alone
Understood Care's patient advocates - including nurses, pharmacists, and care coordinators - help Medicare beneficiaries understand their Alzheimer's coverage, appeal denials, find CED trial sites, and access programs that reduce out-of-pocket costs. Our advocates know how Medicare and insurance systems work. We speak that language so you don't have to.
Frequently Asked Questions
Does Medicare cover Alzheimer's drugs like Leqembi and Aduhelm?
Yes - but with a major condition. Medicare covers FDA-approved anti-amyloid drugs like Leqembi (lecanemab) only when you are enrolled in a qualifying clinical trial or CMS-approved registry under the Coverage with Evidence Development (CED) policy. Standard Medicare Part B does not cover these drugs for routine use. Leqembi costs approximately $27,000 per year before Medicare discounts apply.
What does Medicare Part B cover for Alzheimer's diagnostic testing?
Medicare Part B covers cognitive assessments during your Annual Wellness Visit at no cost, as well as medically necessary neurology visits, neuropsychological testing, and brain imaging (MRI, CT scans) when ordered by your doctor. PET scans for amyloid imaging are covered only through CMS-approved registries - not as routine diagnostic tests outside of a qualifying program.
Can someone under 65 with Alzheimer's get Medicare coverage?
Yes. If you are under 65 and diagnosed with early-onset Alzheimer's, you may qualify for Medicare through Social Security Disability Insurance (SSDI) after a 24-month waiting period from your disability determination date. Approximately 200,000 Americans are living with young-onset Alzheimer's and face additional barriers accessing Medicare because of the age and disability waiting period requirements. A patient advocate can help you navigate the SSDI application and Medicare enrollment timeline.
Does Medicare cover memory care facilities or nursing home care for Alzheimer's?
Medicare Part A covers skilled nursing facility care only after a qualifying 3-day hospital stay, and only for skilled care needs - not custodial or long-term memory care. A $1,676 deductible applies per benefit period in 2026. Long-term residential memory care is generally not covered by Medicare; Medicaid is the primary payer for that level of care once assets are spent down to eligibility thresholds.
What is the CED restriction and how does it affect Alzheimer's treatment coverage?
Coverage with Evidence Development (CED) is a CMS policy that restricts Medicare coverage of certain new treatments to patients enrolled in qualifying clinical trials or CMS-approved registries. For anti-amyloid Alzheimer's drugs, CED means Medicare will only pay for the drug infusions if your treatment is being tracked through an approved data-collection program. This was designed to build real-world evidence on outcomes before granting broad coverage - but in practice it limits access for many patients.
How do I find a Medicare plan that covers Alzheimer's care?
Call your State Health Insurance Assistance Program (SHIP) at 1-877-839-2675 for free, unbiased counseling. SHIP counselors can compare your current plan against alternatives, check formulary coverage for your specific Alzheimer's medications, and help you evaluate whether Original Medicare or a Medicare Advantage plan better fits your situation. This service is free and available in all 50 states plus Washington D.C., Puerto Rico, and U.S. territories.
Will Medicare cover a second opinion for an Alzheimer's diagnosis?
Yes. Medicare Part B covers second opinion consultations with neurologists and other specialists as medically necessary services. You pay standard Part B cost-sharing - typically 20% after the $257 annual deductible in 2026. A second opinion from a board-certified neurologist or geriatric psychiatrist is strongly recommended before starting any anti-amyloid treatment, given the complexity of Alzheimer's staging and the brain bleeding risk associated with newer medications.
